VJHemOnc is committed to improving our service to you

COMy 2020 | New modalities of immunotherapy for myeloma

VJHemOnc is committed to improving our service to you

Sagar Lonial

Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the new modalities of immunotherapy for myeloma. For example, belantamab mafodotin is an antibody-drug conjugate that targets B-cell maturation antigens (BCMA). There are also multiple CAR-T products that could soon become the first to be approved for myeloma, such as ide-cel also known as bb2121. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter